Clinical Trials Logo

Bowel Cancer clinical trials

View clinical trials related to Bowel Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06267378 Recruiting - Bowel Cancer Clinical Trials

Assessing Frailty and Its Impacts on Patients Facing Major GI Surgery

Start date: August 30, 2023
Phase:
Study type: Observational

The study team will look at 3 new tests that will make it easier to measure frailty in patients awaiting surgery for cancer and compare them against standard clinical measures of frailty in a pilot study. The expected outcome is that evidence will be collated in order to apply for a major grant to look at improving the care of frail patients with cancer in the future.

NCT ID: NCT06008847 Recruiting - Bowel Cancer Clinical Trials

Capsule Endoscopy Delivery at sCale Through Enhanced AI anaLysis Study

CESCAIL
Start date: February 9, 2022
Phase:
Study type: Observational

The CESCAIL study tests the use of Artificial Intelligence (AI) on a video taken from a minimally-invasive imaging device, to improve efficiency and accuracy of the detection of polyps, which are little outgrowths within the lining of the bowel.

NCT ID: NCT04747665 Recruiting - Colonoscopy Clinical Trials

Experiences and Perceptions of Colonoscopy and New Technologies

Start date: February 1, 2021
Phase:
Study type: Observational

Bowel cancer is the 3rd most common cancer in males and females. Most bowel cancers develop from precancerous polyps in the bowel. Colonoscopy can detect and remove these polyps, thereby reducing the risk of developing bowel cancer. However, colonoscopy is an invasive procedure with inherent risk, and can be both uncomfortable and embarrassing to undergo. The risks and numerous other barriers often mean colonoscopy, and cancer preventing polyp removal, is not performed. The investigators aim to start the first in-human feasibility clinical investigation of a robotic magnetic colonoscope in 2021. The new device aims to reduce the discomfort and risk associated with colonoscopy. As part of the patient and end user involvement aspect of the project the investigators aim to perform a mixed methodology inductive type research project exploring experiences of colonoscopy for patient and endoscopists. The study will follow an exploratory mixed methodology format with two parallel work-streams for patients and endoscopists. Each work-stream will consisting of a focus groups (1-2 for each patients and endoscopists), followed by 20 endoscopist and 30 patient in-depth interviews, then an online questionnaire. Each stage will be thematically analysed to form the semi-structured questions for the next stage. The target population will be endoscopists who perform colonoscopy and people who have undergone, or refused to undergo, a colonoscopy. Focus groups will be performed in groups of 6-10 participants, and both interview and focus groups will be performed via video/teleconferencing.

NCT ID: NCT03563586 Recruiting - Colorectal Cancer Clinical Trials

Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery

MECCA
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Investigation of the role of adding oral antibiotics to preoperative mechanical bowel preparation before colorectal surgery for cancer.

NCT ID: NCT02633098 Recruiting - Colorectal Cancer Clinical Trials

A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer

NeoART
Start date: April 26, 2017
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.